



22BE4



BRAWN BIOTECH LTD.

28th May, 2025

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalai Street, Mumbai 400 001

BSE Scrip Code No: 530207
Scrip ID:Brawn

SUB: Submission of published results under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Dear Sir,

Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed copy of publication of results for the quarter/year ended 31st March, 2025 published in newspapers on 28th May, 2025 viz. Business Standard (English newspaper) and Business Standard (Hindi newspaper).

Kindly take the same on your record.

Thanking You,
Yours Faithfully,

For Brawn Biotech Limited



Priyanka Sharma
(Company Secretary & Compliance Officer)
Membership No. A50385
Encl:As above



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

...for better life

DOLFIN RUBBERS LIMITED					
Regd. Office: 26 A, Bhai Randhir Singh Nagar, Ludhiana, Punjab-141012, CIN: L25112PB1995PLC017160					
Email: dolfintube@gmail.com; Website: www.dolfintyres.com					
EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025					
(₹ in Lakhs) Except per equity share data					
Sr. No.	Particulars	QAUarter ENDED		YEAR ENDED	
		31.03.2025 (Audited)	31.03.2024 (Unaudited)	31.12.2024 (Audited)	31.03.2025 (Audited)
1	Total Income from Operations	3952.54	3487.31	3205.26	14401.09
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	217.37	207.61	125.19	717.35
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	217.37	207.61	125.19	717.35
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	154.01	148.86	70.79	512.49
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	152.53	149.77	69.07	511.27
6	Equity Share Capital	1002.99	1002.99	1002.99	1002.99
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2335.94
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)				
	1. Basic:	1.54	1.48	0.71	5.11
	2. Diluted:	1.54	1.48	0.71	5.11
Notes: 1. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results is available on the websites of the Stock Exchange(s) (www.bseindia.com) and the listed entity. (www.dolfintyres.com). 2. The above audited results have been reviewed by the Audit Committee and taken on record at the meeting of the Board of Directors held on 27/05/2025.					
Place : Ludhiana Date: 27 May, 2025					
For DOLFIN RUBBERS LIMITED Sd/- KAWALJIT SINGH Chairman & Managing Director DIN: 00942794					

BRAWN BIOTECH LIMITED					
CIN:L74899DL1985PLC022468					
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024					
Extract of Standalone Audited Financial Results for the quarter and year ended 31st March 2025					
(Rs. In Lacs)					
Sl. No.	Particulars	Standalone			
		Quarter ended 31.03-2025	Year ended 31-03-2025	Year ended 31-03-2024	
		Un-audited	Audited	Audited	
1	Total income from operation	235.04	1,355.83	1,658.27	
2	Net Profit/(Loss) from ordinary activities after tax	(49.44)	(179.81)	(154.42)	
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	(49.44)	(179.81)	(154.42)	
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	(49.52)	(176.08)	(154.14)	
5	Equity Share Capital	300.03	300.03	300.03	
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previos year	-	-	-	
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)	-	-	-	
	(a) Basic (Rs.)	(1.65)	(5.87)	(5.14)	
	(b) Diluted (Rs.)	(1.65)	(5.87)	(5.14)	
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)	-	-	-	
	(a) Basic (Rs.)	(1.65)	(5.87)	(5.14)	
	(b) Diluted (Rs.)	(1.65)	(5.87)	(5.14)	
NOTES : 1- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com). 2- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 26-05-2025 3- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016. 4- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments. 5- Figures for the quarter ended 31st March 2025 are the differences between the figures for the year ended 31st March 2025 and Nine month ended 31st December 2024. 6- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.					
Place : Delhi Date : 26-05-2025					
For and on behalf of Board For Brawn Biotech Limited Sd/- Brij Raj Gupta Director DIN No. 00974969					

MAHUA BHARATPUR EXPRESSWAYS LIMITED					
Regd. Office: B-376, Upper Ground Floor, Nirman Vihar, New Delhi-110092					
CIN - U45203DL2005PLC329746					
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025					
(Amounts in Lacs)					
Sl No.	Particulars	For the quarter ended			
		31-03-2025 (Unaudited)	31-12-2024 (Unaudited)	31-03-2024 (Unaudited)	
1	Total Income from Operations	3,331.62	3,271.42	3,134.31	12,419.78
2	Net Profit / (Loss) for the period/year (Before Tax, Exceptional and / or Extraordinary Items)	1,244.73	1,377.50	715.13	4,123.10
3	Net Profit / (Loss) for the period/year Before Tax (after Exceptional and / or Extraordinary Items)	1,244.73	1,377.50	715.13	4,123.10
4	Net Profit / (Loss) for the period/year after tax (after Exceptional and / or Extraordinary Items)	1,601.21	1,376.20	612.44	4,478.28
5	Total Comprehensive Income for the period/year (Comprising profit / (Loss) for the period/year (after tax) and other Comprehensive Income (after tax)	1,603.54	1,376.11	611.84	4,478.08
6	Paid-up equity share capital (Face value of Rs. 10 each)	9,936.00	9,936.00	9,936.00	9,936.00
7	Other equity (Reserves excluding revaluation reserves)	(5,147.35)	(6,750.89)	(9,625.43)	(5,147.35)
8	Security Premium Account	-	-	-	-
9	Net worth	4,788.65	3,185.11	310.57	4,788.65
10	Paid up debt capital / Outstanding debt	17,613.47	18,540.20	22,491.83	17,613.47
11	Outstanding Redeemable Preference Shares	-	-	-	-
12	Debt / Equity Ratio	3.68	5.82	72.42	3.68
13	Earning per share (EPS) (Face value of Rs. 10/- each) (for Continuing and discontinued operations)				
	1. Basic	1.61	1.39	0.62	4.51
	2. Diluted	1.61	1.39	0.62	4.51
14	Capital Redemption Reserve	-	-	-	-
15	Debtenture redemption reserve (Refer note 2)	-	-	-	-
16	Debt Service Coverage Ratio	1.65	0.65	3.40	1.18
17	Interest Service Coverage Ratio	4.92	4.54	3.40	3.77
Notes: 1 The above audited financial results of the Company for the quarter and year ended March 31, 2025 have been reviewed and approved by the Audit Committee and Board of Directors in their meeting held on May 26, 2025. 2 In the absence of distributable profits, the Company has not created Debtenture Redemption Reserve (DRR). The Company is regular in redeeming debentures matured during the period. 3 Information as required by Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as per separate Annexure attached, the pertinent disclosures have been made to the BSE Limited and can be accessed on https://www.bseindia.com. 4 The above is an extract of the detailed format of quarterly/annual financial results filled with the BSE Limited under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the websites of the BSE Limited and on the company website : https://mbel.co.in/investor-relation/					
Place : Noida Date : May 26, 2025					
For and on behalf of the Board MAHUA BHARATPUR EXPRESSWAYS LIMITED Sd/- Abhijit Saukhyashil Sathe Director DIN: 10043844					

GSK	
GlaxoSmithKline Pharmaceuticals Limited	
Corporate Identity Number (CIN): L24239MH1924PLC001151	
GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030	
Telephone: 022-24959595 • Fax: 022-24959494	
Email: in.investorquery@gsk.com • Website: https://india-pharma.gsk.com	
NOTICE TO SHAREHOLDERS WITH RESPECT TO 100 th ANNUAL GENERAL MEETING	
NOTICE is hereby given that the 100 th Annual General Meeting ("AGM") of the Company will be held on Friday, 27th June 2025 at 11.00 a.m. through Video Conferencing ("VC") or Other Audio-Visual Means ("OAVM"), to transact the business set out in the Notice of the AGM which will be circulated for convening the AGM. The AGM will be held without the physical presence of the Shareholders at a common venue. This is in compliance with the Companies Act, 2013 and the Rules made thereunder read with the General Circular No. 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard and latest being other subsequent circulars, the latest being dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") and read with Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/19 dated May 12, 2020 and subsequent circulars issued by Securities and Exchange Board of India ("SEBI") the latest being dated October 24, 2024 (collectively referred to as said "SEBI Circulars").	
The instructions for joining the AGM are provided in the Notice of the AGM and attendance of the Shareholders attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.	
The Notice of the AGM along with the Annual Report for the Financial Year 2024-25 ("Annual Report") is being sent only by electronic mode to those Shareholders whose email addresses are registered with the Company/Depository Participants in accordance with the aforesaid MCA circulars and said SEBI Circular.	
The Notice of the AGM and Annual Report will also be available on the website of the Company at Website: www.india-pharma.gsk.com and websites of BSE Limited and National Stock Exchange of India Limited i.e. at www.bseindia.com and www.nseindia.com respectively and on the website of NSDL at www.evoting.nsdl.com .	
The Company is pleased to provide the facility of e-voting to its Shareholders, to enable them to cast their votes on the resolutions proposed to be passed at the AGM by electronic means, using remote e-voting system (e-voting from e-place other than venue of the AGM) as well as e-voting during the proceeding of the AGM (collectively referred as e-voting"). The Company has engaged the services of NSDL, for providing the e-voting facility to the Shareholders. The instructions for e-voting are provided in the Notice of the AGM.	
Shareholders who wish to register their email address/bank account mandate may follow the below instructions-	
Dematerialized Holding	Register / update the details in your demat account, as per process advised by your Depository Participant (DP)
Physical Holding	Register / update the details in prescribed form ISR-1 and other relevant forms with Registrar and Transfer Agents of the Company, KFin Technologies Limited at einward@kfinetech.com Member may download prescribed forms from the Company's website at https://india-pharma.gsk.com/en-in/investors/shareholder-information/download-forms/
The Board of Directors has recommended for consideration of the Shareholders a dividend of Rs 42 per share (420%) on face value of Rs 10 each for the year ended 31 st March, 2025. The Company has fixed Friday, May 30, 2025 as the "Record date" for determining the entitlement of members to Dividend. The Dividend, if approved, will be payable on or after Monday, 30 th June, 2025 to those Shareholders whose names are registered as such in the Register of Members of the Company as on Record date i.e. Friday, May 30, 2025 provided by the depository, subject to deduction of tax at source where applicable.	
Pursuant to Finance Act 2020, dividend income will be taxable in the hands of Shareholders with effect from April 1, 2020 and the Company is required to deduct tax at source from dividend paid to the Shareholders at the prescribed rates. For the prescribed rates for various categories, the Shareholders are requested to refer to the Finance Act, 2020 and amendments thereof. Shareholders are also requested to refer to the Notice of the AGM for more details on process to be followed from their side, if any, in this regard.	
Members holding shares in electronic form may please note that their bank details as furnished by the respective DPs to the Company will be considered for remittance of dividend as per the applicable regulations of the DPs and the Company will not be able to accede to any direct request from such Members for change/addition/deletion in such bank details. Accordingly, Members holding shares in electronic form are requested to ensure that their Electronic Bank Mandate is updated with their respective DPs.	
In case of any queries, you may refer the Frequently Asked Questions ("FAQs") for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre, Senior Manager at pallavid@nsdl.com	
For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary	
Place : Mumbai Dated : 27 th May, 2025	

MAHARASHTRA SEAMLESS LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office : Pipe Nagar, Village Sukeli, BKG Road, NH-17, Taluka Roha, Distt. Raigad-402126 (Maharashtra)

Tel. No. 02194 - 238511; E-mail: secretarial@mahaseam.com; Website www.jindal.com

Corporate Office : Plot No. 30, Institutional Sector - 44, Gurugram - 122003 (Haryana)

Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana); CIN: L99999MH1988PLC080545

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2025

(Rs. in Crores, except per share data)

Sl. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
1.	Total income from operations	1,415.83	1,407.97	1,214.81	5,265.90	5,403.12	1,417.77	1,408.11	1,214.90	5,268.67	5,404.12
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	299.17	255.86	294.75	1,015.76	1,246.09	299.24	255.51	294.83	1,013.79	1,245.40
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	299.17	255.86	294.75	1,015.76	1,246.09	298.87	251.75	289.73	1,000.20	1,222.81
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	242.53	190.17	223.29	792.85	974.93	242.26	186.06	218.28	777.32	951.66
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	242.69	190.20	222.71	793.07	974.99	206.40	187.19	288.96	742.88	1,023.76
6.	Equity Share Capital (Face Value of Rs. 5/- each)	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00
7.	Other Equity				6,205.92	5,546.86				6,272.94	5,663.70
8.	Earning per Share Basic/Diluted Earning Per Share Not Annualised (Rs.)	18.10	14.19	16.66	59.17	72.76	18.06	13.89	16.30	58.02	70.99

Note:

1. The above is an extract of the detailed Financial Results for the quarter & year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full financial results for the quarter & year ended 31st March, 2025 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com and can also be accessed by scanning the given QR code.

For MAHARASHTRA SEAMLESS LIMITED

Place : New Delhi
Date : 26th May, 2025

JINDAL
D.P. JINDAL GROUP

SAKET JINDAL
Managing Director
DIN: 00405736

JINDAL DRILLING AND INDUSTRIES LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office : Pipe Nagar , Village Sukeli, N.H. 17, B.K.G.Road Taluka Roha, Distt: Raigad-402126, Maharashtra (India)

Tel: 02194-238511-12, Fax : 02194-238511, Web: www.jindal.com, E-mail: secretarial@jindaldrilling.in

Corporate Office : Plot No. 30, Institutional Sector-44, Gurugram - 122003 (Haryana)

Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana), CIN: L27201MH1983PLC233813

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2025

(Rs. in Lakhs except earning per share data)

Sl. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
1.	Total income from operations including other income	26,361	25,407	20,852	88,433	64,599	26,361	25,407	20,852	88,433	64,599
2.	Net profit / (loss) for the period (before tax, Exceptional and/or Extraordinary items)	7,147	6,517	4,204	18,841	15,165	7,147	6,517	4,204	18,841	15,165
3.	Net profit / (loss) for the period before tax (after Exceptional and/or Extraordinary items)	7,147	6,517	4,204	18,841	15,165	8,980	8,237	(476)	26,347	8,870
4.	Net profit / (loss) for the period after tax (after Exceptional and/or Extraordinary items but before Other Comprehensive Income)	5,328	4,875	3,180	14,084	11,410	7,161	6,595	(1,500)	21,590	5,115
5.	Total comprehensive income for the period [comprising profit / (loss) for the period after tax and other comprehensive income (after tax)]	5,475	4,550	2,998	13,471	11,428	8,311	6,897	(1,794)	22,744	5,439
6.	Equity Share Capital (Face value of Rs. 5 each)	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449
7.	Other equity	-	-	-	1,29,580	1,16,254	-	-	-	1,57,371	1,34,772
8.	Earning per Share (of Rs. 5 each) Basic / Diluted Earning Per Share Not Annualised (in Rs.)	18.39	16.82	10.97	48.60	39.37	24.71	22.77	(5.18)	74.50	17.65

Note:

1. The above is an extract of the detailed Financial Results for the quarter & year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full financial results for the quarter & year ended 31st March, 2025 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com and can also be accessed by scanning the given QR code.

for JINDAL DRILLING AND INDUSTRIES LIMITED

Place : New Delhi
Date : 26th May, 2025

JINDAL
D.P. JINDAL GROUP

RAGHAV JINDAL
Managing Director
DIN: 00405984

